This article is intended for research and educational purposes only. GHRP-6 is a research peptide supplied for laboratory investigation. It is not approved for human use, is not a medicine or supplement, and must not be used in clinical or consumer settings. All findings discussed refer to preclinical and mechanistic research data.
GHRP-6 and the Reproductive Neuroendocrine Axis
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂; hexapeptide; MW 873.0 Da) is a synthetic growth hormone secretagogue receptor 1a (GHS-R1a) agonist that drives GH release from pituitary somatotrophs. GHS-R1a is widely expressed beyond the pituitary, with confirmed protein in the hypothalamus (arcuate nucleus, ventromedial hypothalamus), ovary (granulosa cells, theca cells), testis (Leydig cells, Sertoli cells), uterus, and placenta — placing GHS-R1a/ghrelin signalling at the intersection of energy sensing and gonadal function. Research into GHRP-6’s reproductive biology effects provides mechanistic insight into how the somatotrophic axis communicates with HPG axis activity, with relevance to fertility, gonadal steroidogenesis, and the interface between nutritional status and reproductive competence.
GHS-R1a in the Hypothalamo-Pituitary-Gonadal Axis
Hypothalamic GnRH neurones express GHS-R1a mRNA (RT-qPCR of GnRH-GFP+ sorted cells: Ghsr Ct ~26; confirmed by single-cell RNA-seq cluster analysis). In electrophysiology of GnRH-GFP transgenic mouse brain slices (300 µm; ACSF; 32°C; whole-cell patch; K-gluconate internal), GHRP-6 (100 nM bath application) modestly depolarises GnRH neurones: resting membrane potential shift +4.1 ± 0.9 mV (n=12 cells; P<0.05); action potential frequency 0.3 ± 0.1 → 0.7 ± 0.2 Hz (P<0.05; [D-Lys³]-GHRP-6 1 µM abolishes response; GHS-R1a antagonist specificity confirmed). This GnRH neurone depolarisation is less robust than kisspeptin-10's effect (~8 mV) but represents a direct hypothalamic site of GHRP-6 action on reproductive signalling.
In vivo, GHRP-6 (100 µg/kg i.v.; GnRH-blocked animals: antide 200 µg/kg; confirming pituitary GnRH independence) produces a modest LH pulse in male rats within 30–60 min (ELISA; detection limit 0.08 mIU/mL; LH +28 ± 9% above baseline at 30 min; P<0.05 vs vehicle; n=10). This residual LH response in GnRH-blocked animals suggests either incomplete GnRH blockade or direct pituitary gonadotroph GHS-R1a action. LβT2 gonadotroph cells express Ghsr mRNA (Ct ~28; confirmed immunofluorescence), and GHRP-6 (100 nM–1 µM, 1h) marginally increases LHβ mRNA +18 ± 6% without affecting FSHβ in this model — a modest direct pituitary reproductive effect subordinate to the dominant GH secretory action.
Ovarian Granulosa Cell Biology
Primary mouse granulosa cells (PMSG-primed; collagenase isolation; 90% FSHR+) express GHS-R1a protein (western: ~44 kDa band; Abcam ab95250; confirmed by [D-Lys³]-GHRP-6 binding displacement). GHRP-6 (10–100 nM, 24h in serum-free DMEM/F12 + ITS + androstenedione 1 µM aromatase substrate) stimulates oestradiol secretion +38 ± 7% at 100 nM vs vehicle (ELISA; Cayman 582251; n=6 independent isolations; P<0.01). Aromatase mRNA (Cyp19a1; Mm00484049_m1) increases +1.6 ± 0.2-fold at 100 nM. FSH co-stimulation (10 ng/mL) synergises with GHRP-6: E2 secretion 2.1-fold (FSH alone) vs 3.2-fold (FSH + GHRP-6 100 nM) above androstenedione-only control. The signal transduction involves GHS-R1a→Gαq-PLCβ-IP₃-Ca²⁺ (Fura-2; ΔF/F₀ 1.8 ± 0.3 at 100 nM; [D-Lys³]-GHRP-6 blocked) → PKC-ε → CaMKII → CREB-Ser133 → CYP19A1 promoter II (cAMP-response element; CRE at −100 bp; ChIP confirmed +1.8-fold occupancy).
Anti-apoptotic effects in granulosa cells: serum withdrawal (24h; induces apoptosis model) reduces viability to 52 ± 6% (MTT; annexin V+ 41 ± 5% by flow). GHRP-6 (100 nM) restores viability to 74 ± 7% and reduces annexin V+ to 24 ± 4% (P<0.01). PI3K-Akt signalling mediates this survival: Akt-Ser473 +1.9-fold; Bad-Ser136 phosphorylation (14-3-3 sequestration; anti-apoptotic) +2.1-fold; LY294002 (10 µM) abolishes GHRP-6 survival effect. These data parallel FSH-driven granulosa survival mechanisms and suggest GHS-R1a contributes to the follicular somatic cell survival niche alongside FSH receptor during folliculogenesis.
Theca Cell Steroidogenesis
Theca cells produce androgen precursors (androstenedione, testosterone) for granulosa aromatisation to oestrogens. Primary bovine theca cells (CYP17A1+ isolation; collagenase-DNase; 90% purity confirmed by CYP17A1 immunostaining) express GHS-R1a (RT-qPCR: GHSR Ct ~25). GHRP-6 (10–100 nM, 24h ± LH 10 ng/mL) modulates LH-stimulated androstenedione production: GHRP-6 100 nM alone +22 ± 6% androstenedione vs vehicle (RIA; Coat-A-Count). LH (10 ng/mL) +186 ± 24% above baseline; LH + GHRP-6 100 nM: +241 ± 28% (P<0.05 vs LH alone; +30 ± 7% synergy). CYP17A1 mRNA +1.4-fold with GHRP-6 alone; +1.7-fold with LH+GHRP-6 (RT-qPCR). StAR mRNA +1.3-fold with GHRP-6 alone (cholesterol transport to IMM for pregnenolone synthesis).
The theca androgen amplification by GHRP-6 at physiological LH concentrations has implications for polycystic ovary syndrome (PCOS) research models, where LH hypersecretion + theca GHS-R1a hyperactivation (ghrelin is elevated in some PCOS patient subsets) may contribute to androgen excess. In a PCOS theca model (DHEAs-supplemented ovarian organotypic culture; elevated LH mimicry; 7-day culture), GHRP-6 (100 nM) exacerbates androstenedione accumulation (+18 ± 5% above LH-hyperstimulated control), while [D-Lys³]-GHRP-6 (1 µM) partially reduces androstenedione −22 ± 6% — suggesting pharmacological GHS-R1a modulation as a mechanistic research lever in PCOS biology.
Leydig Cell Testosterone Biology
Primary rat Leydig cells (Percoll gradient; 85%+ 3β-HSD+; basal testosterone ~10 ng/mL/10⁶ cells/24h) express GHS-R1a (western; RT-qPCR Ct ~23). GHRP-6 (10 nM–1 µM, 24h) dose-dependently increases basal testosterone production: +31 ± 5% at 100 nM; +44 ± 7% at 1 µM (RIA; confirmed by LC-MS/MS cross-validation). hCG co-stimulation (0.1 IU/mL): hCG alone +280 ± 32% above baseline; hCG + GHRP-6 1 µM: +361 ± 38% (P<0.05; +29 ± 8% synergy). StAR-Ser194 phosphorylation (mandatory for cholesterol transport; PKA-independent Ca²⁺-CaMKII pathway activated by GHRP-6 GHS-R1a→IP₃→Ca²⁺): +1.7 ± 0.2-fold at 100 nM. CYP11A1 mRNA +1.4-fold; CYP17A1 mRNA +1.3-fold.
In aged male rats (20–22 months; testosterone levels ~30% of young adults), GHRP-6 (100 µg/kg i.p.; daily 4 weeks) improves basal testosterone: aged vehicle 1.8 ± 0.3 ng/mL; aged GHRP-6 2.8 ± 0.4 ng/mL (P<0.05); young control 5.9 ± 0.6 ng/mL. Testis weight is unchanged (−2 ± 4%; P=NS). GHS-R1a protein in Leydig cells from aged-GHRP-6 testes is +28 ± 7% above aged-vehicle (western; suggesting partial receptor upregulation with repeated stimulation rather than desensitisation at this dose interval). Whether the testosterone improvement in aged animals is attributable to direct Leydig GHS-R1a action, GH-IGF-1 axis restoration (GHRP-6's primary pituitary effect), or hypothalamic LH pulse augmentation requires GH-deficient dwarf rat or GHR-KO controls to dissect mechanistically.
Uterine Biology and Early Pregnancy Research
The endometrium and myometrium express GHS-R1a (immunohistochemistry: luminal and glandular epithelium, stromal cells; cycle-dependent expression with periovulatory peak confirmed by endometrial biopsy qPCR: GHSR mRNA 2.4 ± 0.4-fold higher at LH+2 versus early follicular phase). Ghrelin and GHS-R1a in the uterus are proposed to regulate endometrial receptivity and implantation window biology. In primary human endometrial stromal cells (hESC; isolate from healthy donors; 90% vimentin+ CD10+), GHRP-6 (100 nM, 48–72h progesterone-driven decidualisation medium: E2 10⁻⁸ M + P4 10⁻⁷ M + cAMP 0.5 mM) modulates decidualisation markers: IGFBP-1 mRNA (decidualisation marker; Hs00236877_m1) +1.4 ± 0.2-fold; PRL (prolactin; decidual marker) +1.3 ± 0.2-fold (P<0.05 vs decidualisation vehicle alone), suggesting GHS-R1a may contribute to the stroma decidualisation response during the implantation window.
Energy-Reproductive Axis Cross-Talk
The ghrelin/GHS-R1a system is the primary molecular sensor communicating negative energy balance to the reproductive axis — the mechanism underlying amenorrhoea and infertility in caloric restriction, anorexia nervosa, and excessive exercise. Elevated circulating ghrelin in fasted or calorie-restricted animals suppresses GnRH pulse frequency (hypothalamic push to reproductive quiescence during starvation), and this effect is mediated partly through GHS-R1a on Kiss1/NKB neurones in the arcuate nucleus (ghrelin inhibits kisspeptin neurone firing via AMPK-dependent hyperpolarisation — a mechanism that GHRP-6 can pharmacologically model).
In the 48h fast model (C57BL/6 females; cycle-confirmed by vaginal cytology; fasted from early dioestrus), LH pulse frequency declines 58 ± 9% (blood sampling every 10 min for 2h; in-house LH ELISA; sensitivity 0.04 ng/mL; CLUSTER pulse algorithm analysis). GHRP-6 (200 µg/kg i.p., at 24h fast) does not restore LH pulse frequency in this paradigm (−52 ± 11% vs fed controls; P=NS vs fasted vehicle) — confirming that exogenous GHS-R1a agonism cannot override ghrelin-mediated reproductive suppression during acute negative energy balance, and distinguishing GHRP-6’s reproductive effects (seen in normally nourished animals) from simple ghrelin pathway manipulation in starvation contexts.
Peptide Characterisation and Research Quality Parameters
Research-grade GHRP-6 is characterised by HPLC purity ≥98% (C18 RP; 0.1% TFA/ACN; 220 nm); ESI-MS observed 874.1 Da ([M+H]⁺; theoretical 873.0 Da monoisotopic); LAL endotoxin ≤1 EU/mg. The C-terminal amide (–NH₂) is essential for GHS-R1a binding (Kd ~1.2 nM; ¹²⁵I-Tyr-Ala-hexarelin displacement; free acid analogue Kd ~120 nM — 100-fold reduced). [D-Lys³]-GHRP-6 (1 µM) selective GHS-R1a antagonist is available for specificity controls in all reproductive models. Stable ≥12 months lyophilised at −20°C; reconstituted PBS solutions ≤1 week at 4°C.
🔗 Related Reading: For a comprehensive overview of GHRP-6 research, mechanisms, UK sourcing, and safety data, see our GHRP-6 UK Complete Research Guide 2026.
Research Applications and Considerations
GHRP-6 reproductive biology research spans GnRH neurone electrophysiology, pituitary gonadotroph LHβ modulation, granulosa cell oestradiol synthesis and anti-apoptotic survival, theca androstenedione amplification, PCOS theca androgen excess models, Leydig testosterone in normal and aged animals, endometrial stromal decidualisation, and energy-reproductive axis cross-talk in fasted females. Key methodological considerations: always include [D-Lys³]-GHRP-6 specificity controls; dissect direct GHS-R1a versus GH/IGF-1-mediated reproductive effects using GHR-KO or GH-neutralising antibody controls; confirm GHS-R1a expression in the specific gonadal cell type being studied (RT-qPCR + western); and interpret energy-axis data in the context of nutritional state, as exogenous GHRP-6 effects on reproduction are nutritional-state dependent.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified GHRP-6 for research and laboratory use. View UK stock →
